The potential of mipomersen, an ApoB synthesis inhibitor, to reduce necessity for LDL-apheresis in patients with heterozygous familial hypercholesterolemia and coronary artery disease

By Vogt Anja   Parhofer Klaus G  

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 6, 2013-04 ,pp. : 691-697

Informa Healthcare

Access to resources Recommend Favorite

Predicting non-adherence in patients with familial hypercholesterolemia

By Galema-Boers J.   Lenzen M.   Domburg R.   Roeters van Lennep J.   Bruchem-van de Scheur G.   Sijbrands E.   Langendonk J.  

European Journal of Clinical Pharmacology, Vol. 70, Iss. 4, 2014-04 ,pp. : 391-397

Springer Publishing Company

Access to resources Recommend Favorite

Colesevelam: A Review of its Use in Hypercholesterolemia

By Robinson Dean M.   Keating Gillian M.  

American Journal of Cardiovascular Drugs, Vol. 7, Iss. 6, 2007-01 ,pp. : 453-465

Adis International

Access to resources Recommend Favorite

New therapies for familial hypercholesterolemia

By Burnett John R   Watts Gerald F  

Expert Opinion on Therapeutic Patents, Vol. 16, Iss. 3, 2006-03 ,pp. : 349-361

Informa Healthcare

Access to resources Recommend Favorite

Apolipoprotein polymorphisms and familial hypercholesterolemia

By Dedoussis George VZ  

Pharmacogenomics, Vol. 8, Iss. 9, 2007-09 ,pp. : 1179-1189

Future Medicine

Access to resources Recommend Favorite